Gemphire Therapeutics Inc. (GEMP) Trading at $10.11 after Inrease

June 29, 2018 - By Alice Reed

Gemphire Therapeutics Inc. (NASDAQ:GEMP) trading at $10.11 after increase. The move was reported on Jun, 29 by Barchart.com. The company has $143.89M market cap. At $10.72 PT, the company’s valuation could be $8.63 million more.

On August, 13. Investors expect Gemphire Therapeutics Inc. (NASDAQ:GEMP) to publish its quarterly earnings, as reported by Faxor. Analysts have anticipation on stock’s earnings per share of $-0.57. That’s up 22.97 % from last year’s $-0.74 earnings per share. Last quarter $-0.58 earnings per share was reported. Analysts sees -1.72 % EPS growth this quarter.

For more Gemphire Therapeutics Inc. (NASDAQ:GEMP) news brought out recently go to: Streetinsider.com, Streetinsider.com, Benzinga.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Pre-Open Movers 06/29: (GEMP) (DERM) (NKE) Higher; (PFIE) (STZ) (SNX) Lower (more…)” brought out on June 29, 2018, “After-Hours Stock Movers 06/28: (GEMP) (NKE) (VRTX) Higher; (SNX) (CVG) Lower (more…)” on June 28, 2018, “42 Biggest Movers From Yesterday” with a publish date: June 13, 2018, “Mid-Morning Market Update: Markets Open Higher; Constellation Brands Earnings Miss Estimates” and the last “Jefferies sees more headroom for Gemphire, up 97%” with publication date: June 29, 2018.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis .The firm is worth $143.89 million. It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH.Last it reported negative earnings.

Gemphire Therapeutics Inc. (NASDAQ:GEMP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.